Two individuals filed the petition in the high court of Andhra Pradesh
From rising prescriptions to the pharma sales force back on the field with full vigour and companies finally finding their feet with the digital marketing strategies - Indian drug makers have shown that medicine sales is certainly a sunshine sector.
Daiichi won't remain a major shareholder in Sun Pharma.
The recalled drugs were manufactured and distributed in the US by Ohm Laboratories.
Rosier year-end seen for Indian pharma thanks to faster US approvals.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The group is looking into a new role for Ranbaxy CEO and MD Arun Sawhney.
Dhirubhai Ambani lived in a one-room chawl in Mumbai with his wife and children and went on to establish the Reliance Group.
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Sun Pharma open to large acquisitions post Ranbaxy.
Data late on Wednesday showed consumer price inflation eased more than-expected to a 25-month low of 8.10 per cent in February, while industrial output unexpectedly expanded, albeit only by 0.1 per cent.
Is yet to decide about the partnership or acquisition route
Both benchmark indices were driven by strong gains in IT, teck, oil and gas, pharma and banking shares amid earnings optimism.
Sun Pharma profit down 30% over compliance costs, lower sales.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
FDA had cancelled Ranbaxy's approvals to launch generic Nexium, Valcyte
Competition watchdog says 'high market concentration' in some segments a worry.
Ranbaxy was asked to sell all products containing Leuprorelin which are marketed and supplied under brand name Eligard.
4 Ranbaxy facilities in India have been barred from exporting to US.
The Hinduja Group, Mukesh Ambani, Murugappa, and the Adani groups were the other gainers in the Modi regime, while Naveen Jindal and Sun Pharma groups saw the most erosion in their m-cap in the last five years, reports Krishna Kant.
The Gurgaon-headquartered drug maker, set to be acquired by another leading domestic company, Sun Pharmaceutical Industries, reported a consolidated net loss of Rs 186 crore for the quarter ended June.
Industry is gathering scientific data to approach the regulator, DCGI, for a review of the suspension order.
Broader market underperformed the headline indices with BSE Midcap and BSE Smallcap finishing in red
The FDA has stepped up its efforts to ensure drug safety in recent months.
The comments need to be submitted to the Competition Commission of India within 15 days, along with supporting documents on how the merger can adversely impact the concerned person or entity, the regulator said, while adding that it would not consider 'unsubstantiated objections' to the deal.
Sun Pharma to retain these in most markets; US could be the exception, where the Ranbaxy name has taken a hit.
Hero MotoCorp's promoter Pawan Munjal emerged as the highest paid director.
Launches cloud-based version of solution to target mid-size clients in life sciences.
Shares in Sun Pharmaceutical Industries fell by more than 5 per cent after the company settled a patent suit with Pfizer Inc related to its acid-reflux drug for $550 million.
On January 31, the US Federal Trade Commission cleared the merger.
Ranbaxy Laboratories on Wednesday reported widening of its consolidated net loss to Rs 1,029.72 crore (Rs 10.29 billion) for the third quarter ended December 31, 2014
Sun Pharma dipped 2% to Rs 615 on the BSE, its lowest level since November 9, 2016
A source said the competition watchdog would by next month suggest 'structural remedies' that included selling key drug segments as conditions for clearing the country's largest pharmaceutical industry merger.
The Nifty50 slipped 33 points to close the session at 8,509 after hitting an intra-day high of 8,587.
On October 2, a legislature committee wrote letters to the 14 companies, initiating an investigation and seeking details about recent price increases in several generic products available in the American market.
Sun Pharmaceutical's acquisition of Ranbaxy has received final approvals.
The year saw 30 QIP deals raising over $5 billion and 35 IPOs.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Some Indian generic drugmakers are, however, uncertain about the pace of approvals in the near future.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances